Targeting the SPC25/RIOK1/MYH9 Axis in Ovarian Cancer
Author Information
Author(s): Jiang Xingyu, Yang Muwen, Zhang Weijing, Shi Dongni, Li Yue, He Lixin, Huang Shumei, Chen Boyu, Chen Xuwei, Kong Lingzhi, Pan Yibing, Deng Pinwei, Wang Rui, Ouyang Ying, Chen Xiangfu, Li Jun, Li Zheng, Zou Hequn, Zhang Yanna, Song Libing
Primary Institution: Sun Yat-sen University Cancer Center
Hypothesis
SPC25 promotes stemness and platinum resistance in epithelial ovarian cancer (EOC) cells through the SPC25/RIOK1/MYH9 axis.
Conclusion
Targeting the SPC25/RIOK1/MYH9 axis may enhance platinum sensitivity and increase survival in patients with EOC.
Supporting Evidence
- SPC25 expression is correlated with poor prognosis in EOC patients.
- High SPC25 levels were found in platinum-resistant EOC tissues.
- Disrupting the SPC25/RIOK1/MYH9 axis enhanced platinum efficacy in vitro and in vivo.
- CBP1, a competitive inhibitory peptide, effectively disrupted the SPC25/RIOK1/MYH9 complex.
Takeaway
This study found that a protein called SPC25 helps cancer cells resist treatment, and blocking it could make the treatment work better.
Methodology
The study used in vitro and in vivo experiments, including whole-transcriptome sequencing, qRT-PCR, Western blotting, and limiting dilution assays.
Potential Biases
Potential biases may arise from the selection of cell lines and animal models used in the study.
Limitations
The study primarily focused on preclinical models, and further clinical validation is needed.
Participant Demographics
The study included 447 patients with epithelial ovarian cancer who underwent platinum-based chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website